About this document

Fda Label by jessica.grajales.quiel is a document available to read on EtoBox.

DURAGESIC (fentanyl transdermal system) is indicated for the management of severe pain in opioid-tolerant patients and carries risks of addiction, abuse, and misuse, which can lead to overdose and death. It is essential to monitor patients closely for respiratory depression and to use the lowest effective dosage for the shortest duration. The FDA has mandated a Risk Evaluation and Mitigation Strategy (REMS) to ensure safe use and mitigate risks associated with opioid analgesics.

Author

jessica.grajales.quiel

Language

EN